Clinical Trial Update: A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of MSI-1256F (squalamine lactate) for wet age-related macular degeneration has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• MSI-1256F (Squalamine lactate)

Snippet

Sponsor: Genaera Corporation | Conditions: Macular Degeneration | Phase 2 | Status: TERMINATED